Selecta Biosciences, Inc., a Watertown, MA-based clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, raised more than $20m in equity funding.
Backers included Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments.
Led by Werner Cautreels, PhD, President and CEO, Selecta develops novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Leveraging its proprietary Synthetic Vaccine Particle (SVP) platform, the company focuses on three key near-term applications:
– inhibition of immunogenicity for biologic therapies,
– treatment of allergies, and
– treatment of autoimmune diseases.
Seelcta intends to use the funds to advance its immune tolerance pipeline, including the lead program SEL-212, a non-immunogenic treatment for refractory and tophaceous gout.
The company has also announced an extention of its collaboration with JDRF, and added Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes.